Endocytosis of immunotoxin-791T/36-RTA by tumor cells in relation to its cytotoxic action
- PMID: 2009518
Endocytosis of immunotoxin-791T/36-RTA by tumor cells in relation to its cytotoxic action
Abstract
Ricin A chain immunotoxin constructed with monoclonal antibody 791T/36, which recognizes a tumor associated glycoprotein Mr 72,000 antigen present on sarcomas and colon and ovarian cancer cells, is cytotoxic for cell lines from tumors expressing this antigen. Incubation of sarcoma 791T cells with immunotoxin for only 5 min is sufficient to produce greater than 95% inhibition of tumor cell growth. Papain treatment of these cells to remove immunotoxin from the cell surface indicated that the cell surface acts as a reservoir for continued internalization of immunotoxin over several hours, but even so, 50% inhibition of cell survival was produced over a 2- to 3-h period. Analysis of the rate of endocytosis demonstrated that 30-50% of cell bound immunotoxin was internalized over a 180-min period. This was primarily dictated by the antibody moiety, regardless of the degree of conjugation to ricin A chain. This rate is much slower than that of other cell surface ligands such as transferrin. Cell cytosol acidification experiments were performed to determine whether this immunotoxin was internalized by clathrin coated pits, which is relatively rapid, or by smooth pits, which is slower, and the results indicated the latter mechanism is almost exclusively used. Intracellular trafficking of antibody 791T/36, conjugated to human serum albumin-tetramethylrhodamine was investigated by flow cytometry. The movement of the conjugate into the lysosomal compartment was delayed so that degradation products were only detected after a lag phase of 30-60 min. The lack of potentiator dependence of 791T/36 immunotoxin is in keeping with these findings.
Similar articles
-
Endocytosis and intracellular routing of an antibody-ricin A chain conjugate.Cancer Res. 1988 Jul 1;48(13):3822-7. Cancer Res. 1988. PMID: 3132322
-
Endocytosis of an antibody ricin A-chain conjugate (immuno-A-toxin) adsorbed on colloidal gold. Effects of ammonium chloride and monensin.Exp Cell Res. 1985 Feb;156(2):327-40. Exp Cell Res. 1985. PMID: 2857124
-
Cytotoxicity of CD3-ricin A chain immunotoxins in relation to cellular uptake and degradation kinetics.Cancer Res. 1992 Nov 1;52(21):5921-5. Cancer Res. 1992. PMID: 1394218
-
Enhancement of immunotoxin action: manipulation of the cellular routing of proteins.Cancer Treat Res. 1988;37:371-89. doi: 10.1007/978-1-4613-1083-9_20. Cancer Treat Res. 1988. PMID: 2908633 Review. No abstract available.
-
Immunotoxin enhancers.Cancer Treat Res. 1988;37:351-69. doi: 10.1007/978-1-4613-1083-9_19. Cancer Treat Res. 1988. PMID: 2908632 Review. No abstract available.
Cited by
-
Targeted kill: from umbrellas to monoclonal antibodies.J Clin Immunol. 1992 Nov;12(6):391-405. doi: 10.1007/BF00918851. J Clin Immunol. 1992. PMID: 1287032 Review. No abstract available.
-
Origin and Therapies of Osteosarcoma.Cancers (Basel). 2022 Jul 19;14(14):3503. doi: 10.3390/cancers14143503. Cancers (Basel). 2022. PMID: 35884563 Free PMC article. Review.
-
Effects of cellular pharmacology on drug distribution in tissues.Biophys J. 1995 Sep;69(3):825-39. doi: 10.1016/S0006-3495(95)79956-8. Biophys J. 1995. PMID: 8519983 Free PMC article.
-
Antibody Conjugates for Sarcoma Therapy: How Far along Are We?Biomedicines. 2021 Aug 8;9(8):978. doi: 10.3390/biomedicines9080978. Biomedicines. 2021. PMID: 34440182 Free PMC article. Review.